Eleison Pharmaceuticals Inc. (ELSN)

Eleison Pharmaceuticals was planning to go public, but the IPO was withdrawn on Jun 29, 2023.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Cap n/a
Revenue (ttm) 1,000,000
Net Income (ttm) -4.59M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About ELSN

Eleison Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to acquiring, developing and commercializing late-stage therapies (in Phase II or Phase III trials) to treat rare, life-threatening diseases, such as pancreatic cancer, small cell lung cancer, pediatric bone cancer and brain cancer. Our current portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). Each has received Orphan Drug Designation by the FDA, and glufosfamide and ILC have received Orphan Dr... [Read more]

Industry Health Care
Sector Biotechnology
Founded 2009
Employees 2
Stock Exchange NASDAQ
Ticker Symbol ELSN
Full Company Profile

Financial Performance

Financial Statements


Cancer biotech Eleison Pharmaceuticals files for a $42 million IPO

Eleison Pharmaceuticals, a Phase 3 biotech developing in-licensed therapies for cancer, filed on Monday with the SEC to raise up to $42 million in an initial public offering.

2 years ago - Renaissance Capital

Eleison Pharmaceuticals IPO Registration Document (S-1)

Eleison Pharmaceuticals has filed to go public with an IPO on the NASDAQ.

2 years ago - SEC